TARS
Tarsus Pharmaceuticals Inc

901
Mkt Cap
$2.83B
Volume
919,349.00
52W High
$85.25
52W Low
$38.51
PE Ratio
-33.08
TARS Fundamentals
Price
$66.61
Prev Close
$65.54
Open
$65.31
50D MA
$73.05
Beta
0.73
Avg. Volume
541,035.80
EPS (Annual)
-$3.07
P/B
8.44
Rev/Employee
$566,417.96
$1,863.24
Loading...
Loading...
News
all
press releases
Mirum Pharmaceuticals, Inc. (MIRM) Earnings Expected to Grow: What to Know Ahead of Q4 Release
Mirum Pharmaceuticals (MIRM) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Zacks·3d ago
News Placeholder
More News
News Placeholder
Tarsus Pharmaceuticals, Inc. (TARS) Expected to Beat Earnings Estimates: Can the Stock Move Higher?
Tarsus Pharmaceuticals (TARS) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Zacks·4d ago
News Placeholder
Tarsus Pharmaceuticals (TARS) Projected to Post Quarterly Earnings on Tuesday
Tarsus Pharmaceuticals (NASDAQ:TARS) will be releasing its Q4 2025 earnings before the market opens on Tuesday, February 24. (View Earnings Report at...
MarketBeat·5d ago
News Placeholder
TimesSquare Capital Management LLC Invests $15.90 Million in Tarsus Pharmaceuticals, Inc. $TARS
TimesSquare Capital Management LLC purchased a new stake in shares of Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS - Free Report) in the 3rd quarter, according to its most recent 13F filing with the...
MarketBeat·6d ago
News Placeholder
Tarsus Pharmaceuticals is Now Oversold (TARS)
Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy when others are fearful. One way we can try to measure the level of fear in a given stock is through a...
Nasdaq News: Markets·8d ago
News Placeholder
Federated Hermes Inc. Has $905,000 Stock Position in Tarsus Pharmaceuticals, Inc. $TARS
Federated Hermes Inc. cut its holdings in shares of Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS - Free Report) by 72.3% in the third quarter, according to the company in its most recent Form 13F filing...
MarketBeat·14d ago
News Placeholder
Will Declining Medical Customers Affect Cigna's Q4 Earnings?
CI heads into Q4 earnings with rising Evernorth revenues but falling premiums and medical customers, raising questions about the quarter's overall growth outlook.
Zacks·19d ago
News Placeholder
Lisanti Capital Growth LLC Has $2.56 Million Position in Tarsus Pharmaceuticals, Inc. $TARS
Lisanti Capital Growth LLC cut its holdings in Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS - Free Report) by 43.1% in the 3rd quarter, according to the company in its most recent filing with the...
MarketBeat·21d ago
News Placeholder
Universal Beteiligungs und Servicegesellschaft mbH Has $5.44 Million Stake in Tarsus Pharmaceuticals, Inc. $TARS
Universal Beteiligungs und Servicegesellschaft mbH increased its holdings in shares of Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS - Free Report) by 77.0% in the third quarter, according to the company...
MarketBeat·26d ago
News Placeholder
Down 16.4% in 4 Weeks, Here's Why You Should You Buy the Dip in Tarsus Pharmaceuticals (TARS)
Tarsus Pharmaceuticals (TARS) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term.
Zacks·26d ago
<
1
2
...
>

Latest TARS News

View
Top Discussions

Advertisement|Remove ads.

Advertisement|Remove ads.